Richard L. Lindstrom M.D.
CIK: 0001242177
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 10, 2026OCUL
OCULAR THERAPEUTIX, INC
Award(A)Direct14K shares- - Jun 3, 2026LNSR
LENSAR, Inc.
Award(A)Direct17.4K shares- - Feb 20, 2026OCUL
OCULAR THERAPEUTIX, INC
Purchase(P)Direct60.2K shares at avg. $7.66$461K - Jun 11, 2025OCUL
OCULAR THERAPEUTIX, INC
Award(A)Direct14K shares- - May 23, 2025LNSR
LENSAR, Inc.
Award(A)Direct7.4K shares- - May 8, 2025OCUL
OCULAR THERAPEUTIX, INC
Purchase(P)Direct10K shares at avg. $6.96$70K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  OCUL OCULAR THERAPEUTIX, INC | Award(A) | 14,000 | - | $0 | Direct |
| Jun 3, 2026 |  LNSR LENSAR, Inc. | Award(A) | 17,421 | - | $0 | Direct |
| Feb 20, 2026 | OCUL OCULAR THERAPEUTIX, INC | Purchase(P) | 60,229 | $7.66 | $461,354 | Direct |
| Jun 11, 2025 | OCUL OCULAR THERAPEUTIX, INC | Award(A) | 14,000 | - | - | Direct |
| May 23, 2025 | LNSR LENSAR, Inc. | Award(A) | 7,374 | - | - | Direct |
| May 8, 2025 | OCUL OCULAR THERAPEUTIX, INC | Purchase(P) | 10,000 | $6.96 | $69,600 | Direct |
1-6 of 6 transactions
About LINDSTROM RICHARD L MD
LINDSTROM RICHARD L MD (SEC CIK 0001242177) files insider reports with the SEC as Director of OCULAR THERAPEUTIX, INC (OCUL) and Director of LENSAR, Inc. (LNSR).
Signal8 holds 6 ownership filings by LINDSTROM RICHARD L MD, all Form 4s, filed between May 12, 2025 and Jun 12, 2026. Those filings report 6 transactions, from May 8, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on LINDSTROM RICHARD L MD's filings is in ORLANDO, FL.
Recent filings by LINDSTROM RICHARD L MD
- Jun 10, 2026: Grant or award of OCUL shares (Form 4, code A).
- Jun 3, 2026: Grant or award of LNSR shares (Form 4, code A).
- Feb 20, 2026: Open-market purchase of OCUL shares (Form 4, code P).
- Jun 11, 2025: Grant or award of OCUL shares (Form 4, code A).
- May 23, 2025: Grant or award of LNSR shares (Form 4, code A).
Other insiders filing for OCULAR THERAPEUTIX, INC (OCUL)
- Anderman Todd, Chief Legal Officer
- Kaiser Peter, Chief Development Officer
- Heier Jeffrey S., Chief Scientific Officer
- Notman Donald, Chief Operating Officer
- Nayak Sanjay, Chief Strategy Officer
- Dugel Pravin